Spots Global Cancer Trial Database for open label
Every month we try and update this database with for open label cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2) | NCT02235740 | Cancer | Afuresertib Carfilzomib | 18 Years - | Novartis | |
| Evaluation of KX2-391 in Patients With Advanced Malignancies | NCT00658970 | Solid Tumors Lymphoma | KX2-391 | 18 Years - | Athenex, Inc. | |
| A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer | NCT00970580 | Non-Small Cell ... | BIIB022 With Pa... | 18 Years - | Biogen | |
| Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia | NCT01380756 | Cancer Hematologic Mal... Leukemia Myeloid Leukemi... | Arm 1- Dose Esc... Arm 2- Dose Exp... | 18 Years - | Amgen | |
| Leuprolide Acetate 3.75 mg Depot to Treat Prostate Cancer | NCT00128531 | Prostate Cancer | leuprolide acet... | 18 Years - | GP-Pharm | |
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | NCT02573259 | Part 1 MELANOMA SCCHN OVCA SARCOMA OTHER SOLID TUM... Part 1 and 2 NSCLC UROTHELIAL CARC... | PF-06801591 PF-06801591 | 18 Years - | Pfizer | |
| A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung | NCT01154140 | Non Squamous Lu... | treatment treatment | 18 Years - | Pfizer | |
| Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors | NCT04795427 | Leukemia, Chron... | asciminib best available ... | 18 Years - | Novartis | |
| A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma | NCT05929235 | Advanced Solid ... Advanced Urothe... Oral Drug Admin... Open Label | FX-909 | 18 Years - | Flare Therapeutics Inc. | |
| A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma | NCT00683761 | Malignant Gliom... Glioblastoma Mu... GBM Astrocytoma Oligodendroglio... | 131I-TM601 | 18 Years - | TransMolecular | |
| 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma | NCT00114309 | Malignant Gliom... Glioblastoma Mu... GBM Anaplastic Astr... Oligo-Astrocyto... Gliosarcoma | 131-I-TM-601 131I-TM601 | 18 Years - | TransMolecular | |
| Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma | NCT00332969 | Thymoma | Octreotide | 18 Years - | Novartis | |
| A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung | NCT01154140 | Non Squamous Lu... | treatment treatment | 18 Years - | Pfizer | |
| An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | NCT03915951 | Non-small Cell ... | encorafenib binimetinib | 18 Years - | Pfizer | |
| Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML | NCT04887259 | Chronic Lymphoc... Multiple Myelom... Acute Myeloid L... | LAVA-051 Interleukin 2 | 18 Years - | Lava Therapeutics | |
| A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma | NCT05929235 | Advanced Solid ... Advanced Urothe... Oral Drug Admin... Open Label | FX-909 | 18 Years - | Flare Therapeutics Inc. | |
| Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma | NCT00154375 | Glioblastoma Mu... Astrocytoma | Imatinib mesyla... Hydroxyurea | 18 Years - 70 Years | Novartis | |
| Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma | NCT01570049 | Non-Hodgkin Lym... | Bendamustine | 18 Years - 75 Years | Shandong Lanjin Pharmaceuticals Co.,Ltd | |
| Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) | NCT01698905 | Chronic Myeloid... | nilotinib | 18 Years - | Novartis | |
| A Study Conducted in Subjects With Relapsed/Refractory Multiple Myeloma (MM); to Determine Dose of Afuresertib in Combination With Carfilzomib (Part 1) and to Investigate the Safety, Pharmacokinetic and Clinical Activity of the Combination Compared With Carfilzomib Alone (Part 2) | NCT02235740 | Cancer | Afuresertib Carfilzomib | 18 Years - | Novartis | |
| A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | NCT05608044 | Metastatic Colo... | Botensilimab Balstilimab Standard of Car... | 18 Years - | Agenus Inc. | |
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | NCT02573259 | Part 1 MELANOMA SCCHN OVCA SARCOMA OTHER SOLID TUM... Part 1 and 2 NSCLC UROTHELIAL CARC... | PF-06801591 PF-06801591 | 18 Years - | Pfizer | |
| A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer | NCT00970580 | Non-Small Cell ... | BIIB022 With Pa... | 18 Years - | Biogen | |
| A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer | NCT05608044 | Metastatic Colo... | Botensilimab Balstilimab Standard of Car... | 18 Years - | Agenus Inc. | |
| An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer | NCT03915951 | Non-small Cell ... | encorafenib binimetinib | 18 Years - | Pfizer | |
| Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma | NCT00591058 | Malignant Gliom... Glioblastoma Mu... GBM Astrocytoma Oligodendroglio... | TM-601 | 18 Years - | TransMolecular | |
| Safety and Efficacy Study of Bendamustine to Treat Non-Hodgkin Lymphoma | NCT01570049 | Non-Hodgkin Lym... | Bendamustine | 18 Years - 75 Years | Shandong Lanjin Pharmaceuticals Co.,Ltd | |
| Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study | NCT05554003 | Neuroendocrine ... Frailty Chemotherapy Ef... | Temozolomide ca... | 18 Years - | European Institute of Oncology | |
| Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma | NCT00591058 | Malignant Gliom... Glioblastoma Mu... GBM Astrocytoma Oligodendroglio... | TM-601 | 18 Years - | TransMolecular | |
| Efficacy of Octreotide Treatment in Patients With Primary Inoperable Thymoma | NCT00332969 | Thymoma | Octreotide | 18 Years - | Novartis | |
| Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma | NCT00154375 | Glioblastoma Mu... Astrocytoma | Imatinib mesyla... Hydroxyurea | 18 Years - 70 Years | Novartis | |
| Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours | NCT01795768 | Gastric Cancer Oesophageal Can... Breast Cancer Squamous Cell C... | AZD 4547 | 25 Years - | Royal Marsden NHS Foundation Trust | |
| Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours | NCT01163903 | Advanced Solid ... | pantoprazole so... doxorubicin hyd... | 18 Years - | University Health Network, Toronto |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
